NSE: ZYDUSLIFE | BSE: 532321

Mid-range Performer

Download real time

979.60 6.65 (0.68%)

26.03% Fall from 52W High

981.3K NSE+BSE Volume

NSE 11 Jul, 2025 3:31 PM (IST)

98,570.7

Market Cap

High in industry

0.8

Beta 1Year

Very Low volatility

Dividend

Zydus Lifesciences Ltd. has an upcoming dividend of ₹11.00 per share due on 25 Jul 2025 See details

Zydus Lifesciences Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for ZYDUSLIFE, BSE:532321 Zydus Lifesciences Ltd.

Search Inside the pdf :

Zydus Lifesciences Ltd.

21 May 2025

979.60

0.68%

Zydus Lifesciences (ZYDUSLIF IN) Q4FY25 Result Update High...

Accumulate: Zydus Lifesciences Ltd.

Target

Prabhudas Lilladhar

Zydus Lifesciences (ZYDUSLIF) Q4 EBITDA including other operating income beat our estimates by 8%. We believe gRevlimid + gMirabegron contributes +45% to total FY25E EPS which will see erosion from FY27. Though, company is working on a robust pipeline of complex products, including injectables, 505(b)2, transdermals, NCE, biosimilars and vaccines, they are expected to materialize over the next 23 years. We expect US sales to decline in FY27...

Zydus Lifesciences L.. has an average target of 988.60 from 5 brokers.

Zydus Lifesciences Ltd.

21 May 2025

979.60

0.68%

Headwinds in US to curtail margins

Hold: Zydus Lifesciences Ltd.

Target

ICICI Securities Limited

Zydus Lifesciences’ (Zydus) Q4FY25 revenue gained with healthy traction in US (+20%), domestic branded formulation (+10.7%) and its consumer business (+17.1%).

Zydus Lifesciences L.. has an average target of 988.60 from 5 brokers.

Zydus Lifesciences Ltd.

16 Apr 2025

979.60

0.68%

ZYDUS LIFESCIENCES LIMITED

Buy: Zydus Lifesciences Ltd.

Recommendation Target

Geojit BNP Paribas

Zydus Lifesciences L.. has an average target of 988.60 from 5 brokers.

Zydus Lifesciences Ltd.

06 Feb 2025

979.60

0.68%

ZYDUS LIFESCIENCES L

Accumulate: Zydus Lifesciences Ltd.

Target

Prabhudas Lilladhar

Zydus Lifesciences L.. has an average target of 988.60 from 5 brokers.

Zydus Lifesciences Ltd.

06 Feb 2025

979.60

0.68%

Near-term challenges persist in US

Hold: Zydus Lifesciences Ltd.

Target

ICICI Securities Limited

Zydus Lifesciences’ (Zydus) Q3FY25 revenue was in line with our expectations, but lower sales of gRevlimid and gAsacol led to a miss in earnings.

Zydus Lifesciences L.. has an average target of 988.60 from 5 brokers.

Zydus Lifesciences Ltd.

18 Nov 2024

979.60

0.68%

Sustained Growth Across All Segments

Buy: Zydus Lifesciences Ltd.

Target

Sharekhan

Revenue amounted to Rs. 5,237 crore, reflecting a 20% y-o-y increase but a 16% q-o-q decline,
primarily driven by reduced performance in the Indian consumer wellness segment, US
formulations and API business.

Zydus Lifesciences L.. has an average target of 988.60 from 5 brokers.

Zydus Lifesciences Ltd.

12 Nov 2024, 12:00AM

979.60

0.68%

The US and international markets drive earnings

Neutral: Zydus Lifesciences Ltd.

Target

Motilal Oswal

Zydus LifeSciences (ZYDUSLIF) delivered better-than-expected operational
performance for the quarter. While its revenue grew at a lower rate of 19% YoY (vs. est. of 25%).

Zydus Lifesciences Ltd. is trading above all available SMAs

Zydus Lifesciences Ltd.

03 Oct 2024

979.60

0.68%

R&D advancements to drive growth

Buy: Zydus Lifesciences Ltd.

Target

Sharekhan

Zydus Lifesciences Ltd has partnered with the Central Drug Research Institute (CDRI) to develop an oral
treatment for osteoporosis related to chronic kidney disease (CKD) and postmenopausal conditions, focusing on small-molecule inhibitors of the protein sclerostin.